Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Receivables: 2020-2025

Historic Change in Receivables for Eton Pharmaceuticals (ETON) over the last 6 years, with Sep 2025 value amounting to -$1.4 million.

  • Eton Pharmaceuticals' Change in Receivables fell 291.21% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 313.37%. This contributed to the annual value of $3.1 million for FY2024, which is 100.00% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Change in Receivables is -$1.4 million, which was up 29.58% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Change in Receivables ranged from a high of $11.0 million in Q1 2025 and a low of -$4.7 million during Q1 2022.
  • For the 3-year period, Eton Pharmaceuticals' Change in Receivables averaged around $1.1 million, with its median value being $633,000 (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 10,495.83% in 2021, then slumped by 1,955.16% in 2022.
  • Eton Pharmaceuticals' Change in Receivables (Quarterly) stood at $5.1 million in 2021, then tumbled by 93.04% to $354,000 in 2022, then plummeted by 123.73% to -$84,000 in 2023, then soared by 1,217.86% to $939,000 in 2024, then tumbled by 291.21% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, -$1.9 million for Q2 2025, and $11.0 million during Q1 2025.